Modifications in bone matrix of estrogen-deficient rats treated with intermittent PTH

Rafael Pacheco-Costa, Jenifer Freitas Campos, Eduardo Katchburian, Valquíria Pereira De Medeiros, Helena Bonciani Nader, Keico Okino Nonaka, Lilian Plotkin, Rejane Daniele Reginato

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Bone matrix dictates strength, elasticity, and stiffness to the bone. Intermittent parathyroid hormone (iPTH), a bone-forming treatment, is widely used as a therapy for osteoporosis. We investigate whether low doses of intermittent PTH (1-34) change the profile of organic components in the bone matrix after 30 days of treatment. Forty 6-month-old female Wistar rats underwent ovariectomy and after 3 months received low doses of iPTH administered for 30 days: daily at 0.3 μg/kg/day (PTH03) or 5 μg/kg/day (PTH5); or 3 times per week at 0.25 μg/kg/day (PTH025). After euthanasia, distal femora were processed for bone histomorphometry, histochemistry for collagen and glycosaminoglycans, biochemical quantification of sulfated glycosaminoglycans, and hyaluronan by ELISA and TUNEL staining.Whole tibiae were used to estimate the bone mineral density (BMD). Histomorphometric analysis showed that PTH5 increased cancellous bone volume by 6% over vehicle-treated rats. In addition, PTH5 and PTH03 increased cortical thickness by 21% and 20%, respectively. Tibial BMD increased in PTH5-treated rats and this group exhibited lower levels of chondroitin sulfate; on the other hand, hyaluronan expression was increased. Hormonal administration in the PTH5 group led to decreased collagen maturity. Further, TUNEL-positive osteocytes were decreased in the cortical compartment of PTH5 whereas administration of PTH025 increased the osteocyte death. Our findings suggest that daily injections of PTH at low doses alter the pattern of organic components from the bone matrix, favoring the increase of bone mass.

Original languageEnglish
Article number454162
JournalBioMed Research International
Volume2015
DOIs
StatePublished - 2015

Fingerprint

Bone Matrix
Rats
Bone
Estrogens
Parathyroid Hormone
Bone and Bones
Osteocytes
A73025
In Situ Nick-End Labeling
Hyaluronic Acid
Bone Density
Collagen
Euthanasia
Chondroitin Sulfates
Elasticity
Ovariectomy
Glycosaminoglycans
Tibia
Femur
Osteoporosis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Pacheco-Costa, R., Freitas Campos, J., Katchburian, E., De Medeiros, V. P., Nader, H. B., Nonaka, K. O., ... Reginato, R. D. (2015). Modifications in bone matrix of estrogen-deficient rats treated with intermittent PTH. BioMed Research International, 2015, [454162]. https://doi.org/10.1155/2015/454162

Modifications in bone matrix of estrogen-deficient rats treated with intermittent PTH. / Pacheco-Costa, Rafael; Freitas Campos, Jenifer; Katchburian, Eduardo; De Medeiros, Valquíria Pereira; Nader, Helena Bonciani; Nonaka, Keico Okino; Plotkin, Lilian; Reginato, Rejane Daniele.

In: BioMed Research International, Vol. 2015, 454162, 2015.

Research output: Contribution to journalArticle

Pacheco-Costa, R, Freitas Campos, J, Katchburian, E, De Medeiros, VP, Nader, HB, Nonaka, KO, Plotkin, L & Reginato, RD 2015, 'Modifications in bone matrix of estrogen-deficient rats treated with intermittent PTH', BioMed Research International, vol. 2015, 454162. https://doi.org/10.1155/2015/454162
Pacheco-Costa R, Freitas Campos J, Katchburian E, De Medeiros VP, Nader HB, Nonaka KO et al. Modifications in bone matrix of estrogen-deficient rats treated with intermittent PTH. BioMed Research International. 2015;2015. 454162. https://doi.org/10.1155/2015/454162
Pacheco-Costa, Rafael ; Freitas Campos, Jenifer ; Katchburian, Eduardo ; De Medeiros, Valquíria Pereira ; Nader, Helena Bonciani ; Nonaka, Keico Okino ; Plotkin, Lilian ; Reginato, Rejane Daniele. / Modifications in bone matrix of estrogen-deficient rats treated with intermittent PTH. In: BioMed Research International. 2015 ; Vol. 2015.
@article{c55a34be840c4820813ba0fef77e0813,
title = "Modifications in bone matrix of estrogen-deficient rats treated with intermittent PTH",
abstract = "Bone matrix dictates strength, elasticity, and stiffness to the bone. Intermittent parathyroid hormone (iPTH), a bone-forming treatment, is widely used as a therapy for osteoporosis. We investigate whether low doses of intermittent PTH (1-34) change the profile of organic components in the bone matrix after 30 days of treatment. Forty 6-month-old female Wistar rats underwent ovariectomy and after 3 months received low doses of iPTH administered for 30 days: daily at 0.3 μg/kg/day (PTH03) or 5 μg/kg/day (PTH5); or 3 times per week at 0.25 μg/kg/day (PTH025). After euthanasia, distal femora were processed for bone histomorphometry, histochemistry for collagen and glycosaminoglycans, biochemical quantification of sulfated glycosaminoglycans, and hyaluronan by ELISA and TUNEL staining.Whole tibiae were used to estimate the bone mineral density (BMD). Histomorphometric analysis showed that PTH5 increased cancellous bone volume by 6{\%} over vehicle-treated rats. In addition, PTH5 and PTH03 increased cortical thickness by 21{\%} and 20{\%}, respectively. Tibial BMD increased in PTH5-treated rats and this group exhibited lower levels of chondroitin sulfate; on the other hand, hyaluronan expression was increased. Hormonal administration in the PTH5 group led to decreased collagen maturity. Further, TUNEL-positive osteocytes were decreased in the cortical compartment of PTH5 whereas administration of PTH025 increased the osteocyte death. Our findings suggest that daily injections of PTH at low doses alter the pattern of organic components from the bone matrix, favoring the increase of bone mass.",
author = "Rafael Pacheco-Costa and {Freitas Campos}, Jenifer and Eduardo Katchburian and {De Medeiros}, {Valqu{\'i}ria Pereira} and Nader, {Helena Bonciani} and Nonaka, {Keico Okino} and Lilian Plotkin and Reginato, {Rejane Daniele}",
year = "2015",
doi = "10.1155/2015/454162",
language = "English",
volume = "2015",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Modifications in bone matrix of estrogen-deficient rats treated with intermittent PTH

AU - Pacheco-Costa, Rafael

AU - Freitas Campos, Jenifer

AU - Katchburian, Eduardo

AU - De Medeiros, Valquíria Pereira

AU - Nader, Helena Bonciani

AU - Nonaka, Keico Okino

AU - Plotkin, Lilian

AU - Reginato, Rejane Daniele

PY - 2015

Y1 - 2015

N2 - Bone matrix dictates strength, elasticity, and stiffness to the bone. Intermittent parathyroid hormone (iPTH), a bone-forming treatment, is widely used as a therapy for osteoporosis. We investigate whether low doses of intermittent PTH (1-34) change the profile of organic components in the bone matrix after 30 days of treatment. Forty 6-month-old female Wistar rats underwent ovariectomy and after 3 months received low doses of iPTH administered for 30 days: daily at 0.3 μg/kg/day (PTH03) or 5 μg/kg/day (PTH5); or 3 times per week at 0.25 μg/kg/day (PTH025). After euthanasia, distal femora were processed for bone histomorphometry, histochemistry for collagen and glycosaminoglycans, biochemical quantification of sulfated glycosaminoglycans, and hyaluronan by ELISA and TUNEL staining.Whole tibiae were used to estimate the bone mineral density (BMD). Histomorphometric analysis showed that PTH5 increased cancellous bone volume by 6% over vehicle-treated rats. In addition, PTH5 and PTH03 increased cortical thickness by 21% and 20%, respectively. Tibial BMD increased in PTH5-treated rats and this group exhibited lower levels of chondroitin sulfate; on the other hand, hyaluronan expression was increased. Hormonal administration in the PTH5 group led to decreased collagen maturity. Further, TUNEL-positive osteocytes were decreased in the cortical compartment of PTH5 whereas administration of PTH025 increased the osteocyte death. Our findings suggest that daily injections of PTH at low doses alter the pattern of organic components from the bone matrix, favoring the increase of bone mass.

AB - Bone matrix dictates strength, elasticity, and stiffness to the bone. Intermittent parathyroid hormone (iPTH), a bone-forming treatment, is widely used as a therapy for osteoporosis. We investigate whether low doses of intermittent PTH (1-34) change the profile of organic components in the bone matrix after 30 days of treatment. Forty 6-month-old female Wistar rats underwent ovariectomy and after 3 months received low doses of iPTH administered for 30 days: daily at 0.3 μg/kg/day (PTH03) or 5 μg/kg/day (PTH5); or 3 times per week at 0.25 μg/kg/day (PTH025). After euthanasia, distal femora were processed for bone histomorphometry, histochemistry for collagen and glycosaminoglycans, biochemical quantification of sulfated glycosaminoglycans, and hyaluronan by ELISA and TUNEL staining.Whole tibiae were used to estimate the bone mineral density (BMD). Histomorphometric analysis showed that PTH5 increased cancellous bone volume by 6% over vehicle-treated rats. In addition, PTH5 and PTH03 increased cortical thickness by 21% and 20%, respectively. Tibial BMD increased in PTH5-treated rats and this group exhibited lower levels of chondroitin sulfate; on the other hand, hyaluronan expression was increased. Hormonal administration in the PTH5 group led to decreased collagen maturity. Further, TUNEL-positive osteocytes were decreased in the cortical compartment of PTH5 whereas administration of PTH025 increased the osteocyte death. Our findings suggest that daily injections of PTH at low doses alter the pattern of organic components from the bone matrix, favoring the increase of bone mass.

UR - http://www.scopus.com/inward/record.url?scp=84933055570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933055570&partnerID=8YFLogxK

U2 - 10.1155/2015/454162

DO - 10.1155/2015/454162

M3 - Article

VL - 2015

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 454162

ER -